Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Eletriptan for acute migraine.

L A Smith1, A D Oldman, H J McQuay

  • 1ICRF/NHS Centre for Statistics in Medicine, Institute of Health Sciences, Old Road, Oxford, UK, OX3 7LF. l.smith@icrf.icnet.uk

The Cochrane Database of Systematic Reviews
|November 1, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Using Advanced Cell Culture Techniques to Differentiate Pluripotent Stem Cells and Recreate Tissue Structures Representative of Teratoma Xenografts.

Frontiers in cell and developmental biology·2021
Same author

Applications of novel bioreactor technology to enhance the viability and function of cultured cells and tissues.

Interface focus·2020
Same author

Ubiquitous parasites drive a 33% increase in methane yield from livestock.

International journal for parasitology·2018
Same author

To fill or not to fill: a qualitative cross-country study on dentists' decisions in managing non-cavitated proximal caries lesions.

Implementation science : IS·2018
Same author

Correction to: Dexketoprofen/tramadol 25 mg/75 mg: randomised double-blind trial in moderate-to-severe acute pain after abdominal hysterectomy.

BMC anesthesiology·2017
Same author

Can BAPEN do more to advance nutrition training amongst trainee doctors? Results of the first UK BAPEN medical trainee group survey.

Clinical nutrition ESPEN·2017
Same journal

Interventions to prevent or cease electronic cigarette use in children and adolescents.

The Cochrane database of systematic reviews·2026
Same journal

Drugs to improve anaemia, quality of life, and physical function in people with myelodysplastic syndromes (MDS).

The Cochrane database of systematic reviews·2026
Same journal

Interventions for smoking cessation in inpatient psychiatry settings.

The Cochrane database of systematic reviews·2026
Same journal

Mechanical thromboprophylaxis for preventing intradialytic hypotension in people undergoing maintenance haemodialysis.

The Cochrane database of systematic reviews·2026
Same journal

Prognostic models for predicting intensive care unit admission or mortality in critically ill adults not yet been admitted to the intensive care unit.

The Cochrane database of systematic reviews·2026
Same journal

Views and experiences of weight management for people living with mobility‑limiting conditions, intellectual disabilities or severe mental illness: a qualitative evidence synthesis.

The Cochrane database of systematic reviews·2026
See all related articles

Eletriptan effectively treats acute migraine attacks, with benefits increasing at higher doses. While generally well-tolerated, higher doses of eletriptan (e.g., 80 mg) are associated with more minor adverse effects compared to lower doses.

Area of Science:

  • Pharmacology and Therapeutics
  • Neurology
  • Clinical Trials

Background:

  • Eletriptan (Relpax) is a novel triptan for acute migraine treatment.
  • Multiple triptans are available, necessitating evidence-based efficacy comparisons.
  • There is a need to assess the relative efficacy and safety of acute migraine treatments.

Purpose of the Study:

  • To evaluate eletriptan's efficacy in treating single migraine attacks.
  • To determine headache response and pain-free rates at various time points (0.5-4 hours) and sustained relief over 24 hours.
  • To quantify efficacy using Number-Needed-to-Treat (NNT) and adverse effects using Number-Needed-to-Harm (NNH) for comparative analysis.

Main Methods:

  • Analysis of data from Phase III randomized, placebo-controlled trials provided by the manufacturer.

Related Experiment Videos

  • Inclusion criteria: double-blind trials for acute migraine, placebo-controlled, adult population, moderate to severe pain intensity.
  • Data extraction and quality scoring by two independent reviewers; pooled analysis for relative benefit/risk and NNT/NNH calculations for eletriptan doses (20, 40, 80 mg).

    • Main Results:

    • Eletriptan (20, 40, 80 mg) demonstrated significant benefits over placebo for headache and pain-free responses at 2 hours.
    • NNTs for pain-free response at 2 hours were 9.9, 4.5, and 3.7 for 20, 40, and 80 mg respectively.
    • No significant difference in major adverse effects; minor adverse effects increased with dose (NNH 11, 7.0, 3.7 for 20, 40, 80 mg).

    Conclusions:

    • Eletriptan (20, 40, 80 mg) is effective for acute migraine, with dose-dependent improvements in efficacy.
    • Eletriptan shows favorable comparison to other triptans for short-term relief and provides 24-hour sustained relief.
    • Single-dose eletriptan is well-tolerated, with dose-dependent increases in minor adverse effects, particularly at 80 mg.